Accessibility Menu
 
Hemogenyx Pharmaceuticals Plc logo

Hemogenyx Pharmaceuticals Plc

(LSE) HEMO

Current Price$680.00
Market Cap$4.55B
Since IPO (2017)-44%
5 Year-7%
1 Year+285%
1 Month-21%

Hemogenyx Pharmaceuticals Plc Financials at a Glance

Market Cap

$4.55B

Revenue (TTM)

$0.00

Net Income (TTM)

$12.57M

EPS (TTM)

$-220.25

P/E Ratio

-3.04

Dividend

$0.00

Beta (Volatility)

0.03 (Low)

Price

$680.00

Volume

9,688

Open

$650.00

Previous Close

$680.00

Daily Range

$650.00 - $680.00

52-Week Range

$124.27 - $1800.00

HEMO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hemogenyx Pharmaceuticals Plc

Industry

Biotechnology

Employees

9

CEO

Vladislav Sandler, PhD

Headquarters

London, EC3V 0HR, GB

HEMO Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-933%

Return on Capital

-2%

Return on Assets

-2%

Earnings Yield

-32.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.55B

Shares Outstanding

6.80M

Volume

9.69K

Avg. Volume

24.57K

Financials (TTM)

Gross Profit

$588.75K

Operating Income

$4.66M

EBITDA

$4.07M

Operating Cash Flow

$3.45M

Capital Expenditure

$3.92K

Free Cash Flow

$3.45M

Cash & ST Invst.

$1.59M

Total Debt

$2.00M

Hemogenyx Pharmaceuticals Plc Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$274.97K

+15.6%

Gross Margin

0.00%

N/A

Market Cap

$4.55B

N/A

Market Cap/Employee

$284.32M

N/A

Employees

16

N/A

Net Income

$4.76M

-100.7%

EBITDA

$1.81M

+4.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$417.82K

+75.4%

Accounts Receivable

$8.78K

+70.8%

Inventory

$0.00

N/A

Long Term Debt

$1.56M

-41.6%

Short Term Debt

$442.42K

-19.0%

Return on Assets

-2.34%

N/A

Return on Invested Capital

-1.72%

N/A

Free Cash Flow

$336.34K

+111.7%

Operating Cash Flow

$336.34K

+112.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KOO.LKooth plc
$173.50+13.03%
HVO.LhVIVO plc
$8.10+1.25%
CREO.LCreo Medical Limited
$11.38+0.00%
POLB.LPoolbeg Pharma PLC
$4.95+3.13%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$13.59+0.05%
TET1 Energy Inc.
$8.72+0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$14.72+0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$76.95+0.01%

Questions About HEMO

What is the current price of Hemogenyx Pharmaceuticals Plc?

Hemogenyx Pharmaceuticals Plc is trading at GBX 680.00 per share.

What is the 52-week range for Hemogenyx Pharmaceuticals Plc?

Over the past 52 weeks, Hemogenyx Pharmaceuticals Plc has traded between GBX 124.27 and GBX 1,800.00.

How much debt does Hemogenyx Pharmaceuticals Plc have?

As of the most recent reporting period, Hemogenyx Pharmaceuticals Plc reported total debt of $2.00M.

How much cash does Hemogenyx Pharmaceuticals Plc have on hand?

Hemogenyx Pharmaceuticals Plc reported $1.59M in cash and cash equivalents in its most recent financial results.

What is Hemogenyx Pharmaceuticals Plc’s dividend yield?

Hemogenyx Pharmaceuticals Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.